U.S. company Incyte, specialized in the development of oncology products, has chosen Yverdon-les-Bains, in the French-speaking canton of Vaud, for its new manufacturing site. Initially, the company plans to recruit 70 employees. 130 people will work on the site once the construction of the new building is completed. Eventually, Incyte is expected to occupy about 66,000 m2 of land at Y-PARC, Switzerland's largest technology park. The company was supported by the GGBa in its investment journey.
A leader in medical innovation
Ranked 6th on Forbes magazine’s 2017 list of the World’s Most Innovative Companies, Incyte is advancing an innovative, rich and diverse portfolio of large and small molecules comprised of 17 development candidates against 14 different molecular targets. In Switzerland, the company is interested in developing innovative partnerships, strengthening its expertise and expanding its offer for cancer solutions. For this reason, the presence of EPFL and CHUV and the availability of specialized researchers in the region, together with the state-of-the-art infrastructure of Y-PARC, were decisive in the choice of Incyte.
At the heart of the Health Valley
The establishment of Incyte contributes to the international reputation of Western Switzerland’s Health Valley. This dynamic region is home to 20 research centers and institutes of higher education, and almost 1,000 life sciences companies, from start-ups to multinationals such as Baxter, Debiopharm and UCB Farchim. In total, the Health Valley employs 25,000 people, including some 5,000 specialized researchers and scientists, and is considered among the three most important centers for the sector in Europe, along with Cambridge and Oxford in Britain.
